anticoagulants, oral factor Xa inhibitors, rivaroxaban, 15 mg twice daily for 3 weeks, followed by 20 mg once daily
DISEASE INTERVENTION COMPARISON RESULTS
N Engl J Med. 2010 Dec 23;363(26):2499-510 Randomized Controlled Trial, Multicenter Study
IN thromboembolic disease, deep venous thrombosis The Use of
anticoagulants, oral factor Xa inhibitors, rivaroxaban, 15 mg twice daily for 3 weeks, followed by 20 mg once daily
As Treatment, Acute
Is equal Than
acute LMWH (enoxaparin) followed by a vitamin K antagonist
To modify recurrent venous thromboembolism (2.1% rivaroxaban VS 3% enoxaparin plus warfarin) or clinically ssignificant bleeding (8% both groups)
N Engl J Med. 2012 Apr 5;366(14):1287-97 Randomized Controlled Trial, Multicenter Study
IN thromboembolic disease, pulmonary embolism The Use of
anticoagulants, oral factor Xa inhibitors, rivaroxaban, 15 mg twice daily for 3 weeks, followed by 20 mg once daily
As Treatment, Acute
Is equal Than
acute heparins LMWH (enoxaparin) followed by a vitamin K antagonist
To reduce recurrence of thromboembolic events at 6 -12 months (2,1% rivarox VS 2,8% warfarin) while not increasing clinically significant bleeding (10% rivarox VS 11% warfarin)